Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)

Authors :: James Larkin
Eduard Gasal
Antoni Ribas
Keith T. Flaherty
Dirk Schadendorf
C. Robert
Jessica C. Hassel
J.-J. Grob
Reinhard Dummer
Wilson H. Miller
Paul Nathan
V. Atkinson
Céleste Lebbé
Hussein Abdul-Hassan Tawbi
Paul Lorigan
Georgina V. Long
Allison Upalawanna
A.M. Arance Fernandez
Johan Hansson
P.A. Ascierto
Source :: Annals of Oncology. 28:v447
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Trametinib
Oncology
medicine.medical_specialty
business.industry
Melanoma
Dabrafenib
Hematology
Placebo
medicine.disease
Double blind
Internal medicine
Medicine
business
medicine.drug

Full Text Access

Tools